Your browser doesn't support javascript.
loading
Transarterial chemoembolization plus apatinib with or without camrelizumab for unresected hepatocellular carcinoma: A two-center propensity score matching study.
Zhu, Di; Ma, Kun; Yang, Wei; Zhou, Hai-Feng; Shi, Qi; Ren, Jian-Wu; Xie, Yu-Guan; Liu, Sheng; Shi, Hai-Bin; Zhou, Wei-Zhong.
Afiliação
  • Zhu D; Department of Interventional Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Ma K; Department of Interventional Radiology, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
  • Yang W; Department of Interventional Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Zhou HF; Department of Interventional Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Shi Q; Department of Interventional Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Ren JW; Department of Interventional Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Xie YG; Department of Interventional Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Liu S; Department of Interventional Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Shi HB; Department of Interventional Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
  • Zhou WZ; Department of Interventional Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Front Oncol ; 12: 1057560, 2022.
Article em En | MEDLINE | ID: mdl-36439471

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article